Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9616 posts found.

albumedix

Albumedix technology extends dosing interval in Behring haemophilia B drug

March 22, 2016 Manufacturing and Production, Research and Development Albumedix, GSK, Idelvion, Novozymes, VELTIS, haemophilia B

Novozymes subsidiary Albumedix has scored another big pharma tie-up for its albumin-based half-life extension technology VELTIS, which this time is …
News
disease

FDA approves new anthrax treatment

March 22, 2016 Manufacturing and Production, Research and Development Antibacterial, FDA, US, anthim, anthrax, defense, inhalational

The US Food and Drug Administration (FDA) has approved Anthim (obiltoxaximab) to treat inhalational anthrax in combination with appropriate antibacterial …
News
takeda_research_centre

Takeda presents long-term Entyvio data in CD and UC

March 21, 2016 Manufacturing and Production, Research and Development Crohn's, Crohn's and Colitis, Entyvio, Takeda, ulcerative colitis

Japan’s Takeda has presented interim findings from the GEMINI Long-Term Safety (LTS) study of ulcerative colitis drug Entyvio (vedolizumab) at …
News

ThromboGenics signs €1m licensing deal with Galapagos for diabetic eye disease treatment

March 21, 2016 Manufacturing and Production, Research and Development, Sales and Marketing

ThromboGenics NV (Euronext Brussels: THR) on Monday said it has signed a €1 million license deal with Galapagos NV (Nasdaq: …
News
christa_wirthumer-hoche

European Medicines Agency elects Christa Wirthumer-Hoche as new chair of management board

March 21, 2016 Medical Communications, Research and Development Christa Wirthumer-Hoche, EMA, European Medicines Agency, chair, chairperson, wirthumer-hoche

Christa Wirthumer-Hoche has been elected chair of the management board of the European Medicine’s Agency. She has served as vice …
Appointment
shutterstock_212432119

Leo Pharma gets EU scientific approval for its psoriasis drug Enstilar

March 21, 2016 Business Services, Research and Development, Sales and Marketing EU, Enstilar, LEO Pharma, psoriasis vulgaris

Leo Pharma on Monday said its drug to treat inflammatory skin condition has received scientific approval in the European Union. …
News
novartissunlight_copy

Novartis’s heart failure drug given final recommendation by NICE

March 21, 2016 Manufacturing and Production, Research and Development Entresto, NICE, Novartis, approval, draft, guidance, heart failure, heart failure drug

The National Institute for Health and Care Excellence (NICE) has issued its final guidance on Entresto (sacubritil/valsartan), a heart failure …
News

TREND: Smallcap biotechs win in stock markets on positive drug trials

March 21, 2016 Research and Development, Sales and Marketing

Troubled Canadian drug firm Valeant Pharma (NYSE: VRX) saw its share price halved in a single day after the company …
Feature
tablet_production_2

Further positive trial results boost Amgen and UCB’s romosozumab

March 21, 2016 Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval

Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …
News
celgene

Celgene’s ozanimod meets endpoints in Phase II ulcerative colitis trials

March 21, 2016 Research and Development, Sales and Marketing Celgene

Celgene International Sàrl, a Celgene subsidiary, has announced additional data of exploratory endpoints from a Phase II trial of ozanimod …
News

US FDA rejects application for Eagle Pharma’s blood thinner; shares plunge

March 21, 2016 Research and Development, Sales and Marketing Eagle Pharmaceuticals, Kangio, US FDA, blood thinner

Shares in Eagle Pharmaceuticals (Nasdaq: EGRX) closed down almost 19% Friday after the US Food and Drug Administration rejected the …
News
pfizer-building-logo1web

Pfizer’s JAK inhibitor meets endpoints in Phase III ulcerative colitis trials

March 21, 2016 Research and Development, Sales and Marketing JAK inhibitor, Pfizer, ecco, endpoint, octave, tofacitinib, ulcerative colitis

Pfizer (NYSE:PFE) has announced that investigational JAK inhibitor – oral tofacitinib – met the primary and secondary endpoints in two …
News
janssen_stairs_1

J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease

March 18, 2016 Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease

Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
News
abraxane0058

Wales approve pancreatic cancer drug for use despite NICE rejection in England

March 18, 2016 Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval

Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
News

Study data supports switch to Celltrion’s Remicade biosimilar

March 18, 2016 Research and Development

Celltrion and distribution partner Mundipharma have presented study data supporting switching irritable bowel disease (IBD) patients from Remicade to biosimilar …
News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026